Comparing Two Imaging Scans for Liver Cancer Screening
Compares ultrasound with abbreviated MRI to find liver cancer in adults at risk.
Key facts
- Who runs it
- Naik Vietti Violi
- Where
- Lausanne, SwitzerlandSee the site
- Trial code
- Registry title
- Improving Hepatocellular Carcinoma Screening
- Status
- Recruiting
- People taking part
- 330 people, planned
- Started
- 1 Apr 2023
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- MRI
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term liver disease who need regular screening for liver cancer (hepatocellular carcinoma, HCC). It compares ultrasound with a short MRI scan.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Chronic liver disease with an indication for HCC screening according to the European Association for the Study of the Liver recommendations.
- Earlier treatment
- People with a history of liver transplantation cannot join.
Main reasons for not taking part
- History of HCC
- History of other cancer
- Earlier liver nodule rated LI-RAD 4, 5 or M
- History of liver transplantation
- Pregnancy
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations
- Informed Consent signed by the subject
Who cannot take part
- Prior liver nodule categorized as LI-RAD 4, 5 or M
- History of HCC
- History of other malignancy
- History of liver transplantation
- Any other condition making the patient unsuitable for the study
- Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study
- Pregnancy
- MRI or MRI contrast agent precaution
Where in Switzerland
- Lausanne University HospitalLausanne, SwitzerlandContact: Naik Vietti Violi, MDTaking people
About the trial
What the trial wants to find out
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI.
Read full original descriptionShow less
Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
The group in the trial
- HCC screening population according to European Association for the Study of the Liver recommendationTreatment being tested
Treatment: MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening
- Plain-language title
- Comparing Two Imaging Scans for Liver Cancer ScreeningGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 November 2026